| Literature DB >> 27761146 |
Hao Huang1, Linfu Li1, Weimei Shi1, Hai Liu1, Jianqiong Yang2, Xiaoliang Yuan3, Longhuo Wu1.
Abstract
Nobiletin (NOB) chemically known as 5,6,7,8,3',4'-hexamethoxyflavone is a dietary polymethoxylated flavonoid found in Citrus fruits. Recent evidences show that NOB is a multifunctional pharmaceutical agent. The various pharmacological activities of NOB include neuroprotection, cardiovascular protection, antimetabolic disorder, anticancer, anti-inflammation, and antioxidation. These events may be underpinned by modulation of signaling cascades, including PKA/ERK/MEK/CREB, NF-κB, MAPK, Ca2+/CaMKII, PI3K/Akt1/2, HIF-1α, and TGFβ signaling pathways. The metabolites may exhibit stronger beneficial effects than NOB on diseases pathogenesis. The biological activities of NOB have been clarified on many systems. This review aims to discuss the pharmacological effects of NOB with specific mechanisms of actions. NOB may become a promising candidate for potential drug development. However, further investigations of NOB on specific intracellular targets and clinical trials are still needed, especially for in vivo medical applications.Entities:
Year: 2016 PMID: 27761146 PMCID: PMC5059563 DOI: 10.1155/2016/2918796
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The structure of NOB (2D and 3D).
The biological effects of NOB on different cell types/animals.
| Cell types/animals | Biological functions | Ref |
|---|---|---|
| 3T3-L1 preadipocytes | Differentiation↑, IBMX↑, insulin↑, STAT 5↑, PPAR | [ |
| Intracellular triglyceride↓, adiponectin↑, MCP-1↓, resistin↓ | [ | |
| Lipid accumulation↓, GPDH↓, PPAR | [ | |
|
| ||
| 3T3-F442A adipocytes | Glucose uptake↑, PI3K/Akt1/2↑, PKA/CREB signaling↑ | [ |
|
| ||
| 3XTg-AD mice model | Soluble A | [ |
|
| ||
| A2780/T cells | ABCB1 transporter efflux↓, Akt/ERK/Nrf2↓ | [ |
|
| ||
| AGS cells | MMP-2↓, MMP-9↓, c-Raf↓, Ras↓, Rac-1↓, RhoA↓, Cdc42↓, PI3K/Akt signaling↓, FAK activation↓, NF- | [ |
|
| ||
| BV2 microglia cells | IL-1 | [ |
|
| ||
| C6 glioma cells | cellular proliferation↓, Ras activity↓, MEK/ERK signaling↓ | [ |
|
| ||
| CUMS-induced rats | BDNF↑, TrkB↑, synapsin I↑ | [ |
|
| ||
| Diet-induced obese mice | Energy expenditure↑, locomotor activity↑, metabolic disorders↓, circadian rhythms↑ | [ |
|
| ||
| DU-145 cells | cMyc↓, p50↓ | [ |
|
| ||
| Freshly isolated hepatocytes | SCD1 mRNA expression↓, hyperlipidemia↓, adiposity↓ | [ |
|
| ||
| H1299 cells | NOTCH-1↓, Jagged 1/2↓, Hey-1↓, Hes-1↓ | [ |
|
| ||
| H1299, A549 cells | EMT↓, p-Src↓, p-paxillin↓, p-FAK↓, MMP-2↓, MMP-9↓, slug↓, snail↓, ZEB1↓, twist↓ | [ |
|
| ||
| HepG2 cells | ApoB secretion (IC50 = 29 | [ |
| Dyslipidemia↓, insulin resistance↓, atherogenesis↓, apoB100↓, MAPKerk↑, LDLR↑, MTP↓, | [ | |
|
| ||
| Hepatocytes | NO (IC50 = 50 | [ |
|
| ||
| HFD-induced obese mice | Plasma triglyceride↓, body weight gain↓, WAT weight↓, PPAR | [ |
|
| ||
| HL-60 cell line | ERK↓, caspase-3↑, caspase-9↑, caspase-8↑, MAPK↑ | [ |
|
| ||
| HOS and U2OS cells | ERK/JNK↓, MMP-2↓, MMP-9↓, CREB↓, SP-1↓, NF- | [ |
|
| ||
| HT22 cells | p-p38↓, p-JNK↓, Bax↓, caspase-3↓, Bcl-2↑, cognitive impairment↓, apoptosis↓ | [ |
|
| ||
| HuH-7, SK-N-SH, 3Y1 |
| [ |
|
| ||
| Human intestinal mast cells | CCL3↓, CCL4↓, CXCL8↓, IL-1 | [ |
|
| ||
| Human ovarian cancer cells | HIF-1 | [ |
|
| ||
| Human fetal membranes and myometrium | IL-1 | [ |
|
| ||
| Human dermal fibroblasts | MMP-9↓, p-p38 MAPK↓ | [ |
|
| ||
|
| Plasma amylase↓, pancreatic myeloperoxidase↓, plasma proinflammatory factors↓, reactive oxygen species production↓, cell apoptosis↓, pancreatic necrosis↓, p-p38MAPK↓, p-AKT↓ | [ |
|
| ||
| MDA-MB-231 cells | MMP-9 (IC50 = 24 | [ |
|
| ||
| MDA-MB-468 cells | ERK1/2↓, cyclin D1↓, p21↑, Bcl-xL↓, Akt↓, mTOR↓ | [ |
|
| ||
| MPP+-triggered rat PD | Microglia activation↓, dopaminergic neuron degeneration↓ | [ |
|
| ||
| MPTP-triggered mice PD | Dopamine release↑, Ca2+/CaMKII autophosphorylation↑, DARPP-32↑, TH↑, cognitive and motor functions↑ | [ |
|
| ||
| NK leukemia cell | Granzyme B↑, p38 MAPK↑, cytolytic activity of KHYG-1 cells↑ | [ |
|
| ||
| NPC-BM, HONE-1 cells | MMP-2↓, NF- | [ |
|
| ||
| Normal human melanocytes | Tyrosinase↓, TRP1↓, PMEL↓, MITF↓, p-CREB↓, p-MEK/p-ERK1/2↓, p-Raf-1↓ | [ |
|
| ||
| OVCAR-3, A2780/CP70 cells | Cell Viability↓, proliferation↓, VEGF↓ | [ |
|
| ||
| OVX mice | Bone resorption↓, osteoclast formation↓, NF- | [ |
|
| ||
| P53-mutated SNU-16 human gastric cancer cells | Proliferation↓, caspase-3↑, caspase-9↑, Bax/Bcl-2 ratio↑, PARP degradation↑, apoptosis↑ | [ |
|
| ||
| PC12 cells | A | [ |
| NR1↑, NR2A↑, NR2B↑, c-FOS↑, learning impairment↓, CRE-dependent transcription↑, PKA/ERK/MEK/CREB↑ | [ | |
|
| ||
| PC-3 cells | Viability↓, VEGF↓, NF- | [ |
|
| ||
| PDGF-BB treated VSMCs | Proliferation↓, migration↓, ROS↓, p-ERK1/2↓, NF- | [ |
|
| ||
| Postischemic | HO-1↑, Nrf2↑, GSH↑, SOD1↑, MMP-9↓, MDA↓, NF- | [ |
|
| ||
| Rats | Hexokinase↑, succinate dehydrogenase↑, mitochondrial metabolism↑ | [ |
|
| ||
| Rat I/R injury | Infarct volume↓, brain edema↓, cell death↓ | [ |
| CREB↑, Akt↑, BDNF↑, Bcl-2↑, neurological deficits↓, brain edema↓, BBB permeability↓ | [ | |
|
| ||
| Rat primary astrocytes | iNOS↓, NO production↓, NF- | [ |
|
| ||
| RAW 264.7 cells | NO (IC50 = 27 | [ |
| Bone resorption↓, osteoclast formation↓, osteoclastogenesis↓ | [ | |
|
| ||
| RBL-2H3 cells | IL-4↓, TNF | [ |
|
| ||
| SAMP8 mice model | Aging cognitive impairment↓, tau phosphorylation↓, oxidative stress↓ | [ |
|
| ||
| SK-N-SH cells | NEP↑ | [ |
| TXNIP↓ | [ | |
|
| ||
| SMMC-7721 cells | Proliferation↓, Bcl-2↓, COX-2↓, Bax↑, caspase-3↑ | [ |
|
| ||
| STZ-induced C57BL mice | TGF | [ |
|
| ||
| STZ-induced rats | Oxidative stress↓, hemodynamic parameters↓, vascular reactivity↓, MMP-2↓, MMP-9↓, collagen↓ | [ |
|
| ||
| TNBS-triggered colitis | COX-2↓, iNOS↓, Akt-NF- | [ |
|
| ||
| U87, Hs683 glioma cells | Cell viability↓, cyclin D1↓, E2 promoter-binding factor 1↓, CDK2↓, CDK4↓, p-PKB↓, p-p38 MAPK↓, p-ERK↓, p-JNK↓ | [ |
Figure 3Summary of pharmacological effects of NOB on different systems. NOB may exhibit neuroprotective activity in attenuation of learning and memory impairment, amelioration of I/R injury, and decrease of dopaminergic neuron generation. In the cardiovascular system, NOB ameliorates metabolic syndrome, promotes locomotor activity, and inhibits platelet aggregation. In addition, NOB may rescue insulin resistance, restore lipid metabolic disorder, and downregulate inflammatory stress and oxidative stress in digestive system. The activities of antiangiogenesis and antimetastasis of NOB have been demonstrated in urinary, reproductive, and respiratory systems. NOB inhibits osteoclastogenesis and subsequently attenuates bone resorption, protecting skeleton homeostasis.
Figure 2The possible signaling cascades of NOB in cells. NOB may upregulate the activities of NMDA receptor and ERK and enhance CREB transcriptional activity. NOB may restore the activity of DARPP-32 through modulation of PKA signaling pathway. Ca2+/CaMKII signaling is also enhanced by NOB, leading to upregulation of CREB transcription. In addition, NOB increases the activities of PI3K/Akt and BDNF/TrkB signaling but upregulates the expression of PPARγ. However, it depends on different cell lines. Insulin sensitization has been elevated by NOB through Nrf2 signaling pathway.
Figure 4The structures of NOB metabolites, including NOB (1), 3′-demethylnobiletin (2), 4′-demethylnobiletin (3), 3′,4′-didemethylnobiletin (4), 5-demethylnobiletin (5), 5,3′-didemethylnobiletin (6), 5,4′-didemethylnobiletin (7), and 5,3′,4′-tridemethylnobiletin (8).